Last reviewed · How we verify
Dunamenti REK Istenhegyi IVF Center — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Progesterone | Progesterone plus HCG | marketed | Progesterone [EPC] | progesterone receptor, luteinizing hormone/choriogonadotropin receptor | Metabolic | 1978-01-01 |
| higher dose recFSH | higher dose recFSH | marketed | Gonadotropin | FSH receptor (FSHR) | Reproductive Medicine / Fertility | |
| unchanged dose | unchanged dose | marketed | ||||
| no luteal support | no luteal support | marketed | Reproductive Medicine / Fertility |
Therapeutic area mix
- Reproductive Medicine / Fertility · 2
- Metabolic · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AGUNCO Obstetrics and Gynecology Centre · 1 shared drug class
- Ain Shams Maternity Hospital · 1 shared drug class
- Azienda USL Modena · 1 shared drug class
- Bezmialem Vakif University · 1 shared drug class
- Central Jutland Regional Hospital · 1 shared drug class
- D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 shared drug class
- El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Dunamenti REK Istenhegyi IVF Center:
- Dunamenti REK Istenhegyi IVF Center pipeline updates — RSS
- Dunamenti REK Istenhegyi IVF Center pipeline updates — Atom
- Dunamenti REK Istenhegyi IVF Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Dunamenti REK Istenhegyi IVF Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dunamenti-rek-istenhegyi-ivf-center. Accessed 2026-05-17.